Atyr PHARMA INC (NASDAQ:ATYR) Receives $18.60 Consensus PT from Analysts

Atyr PHARMA INC (NASDAQ:ATYR) has earned an average recommendation of “Buy” from the seven brokerages that are covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $18.60.

Several brokerages have commented on ATYR. Leerink Partners started coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a report on Friday, March 14th. Cantor Fitzgerald started coverage on Atyr PHARMA in a report on Monday, January 6th. They issued an “overweight” rating on the stock. Finally, Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th.

Atyr PHARMA Price Performance

ATYR opened at $2.97 on Wednesday. The stock has a market cap of $263.91 million, a P/E ratio of -3.16 and a beta of 0.95. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The company has a fifty day simple moving average of $3.46 and a 200 day simple moving average of $3.26.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. On average, research analysts expect that Atyr PHARMA will post -0.91 EPS for the current year.

Hedge Funds Weigh In On Atyr PHARMA

Several hedge funds have recently modified their holdings of ATYR. Charles Schwab Investment Management Inc. acquired a new position in Atyr PHARMA during the fourth quarter valued at approximately $144,000. Victory Capital Management Inc. acquired a new position in Atyr PHARMA during the fourth quarter worth $37,000. D.A. Davidson & CO. acquired a new stake in Atyr PHARMA in the fourth quarter valued at $141,000. Knott David M Jr bought a new position in shares of Atyr PHARMA in the 4th quarter valued at about $1,115,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Atyr PHARMA by 52.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock worth $55,000 after purchasing an additional 10,754 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.